breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Αντινεοπλασματικοί παράγοντες - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - Άλλα καρδιακά παρασκευάσματα - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
paradroxil 125mg/5ml pd.ora.sus
bristol myers squibb aebe - amoxicillin trihydrate - ΚΟΝΙΣ ΓΙΑ ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 125mg/5ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
paradroxil 250mg/5ml pd.ora.sus
bristol myers squibb aebe - amoxicillin - ΚΟΝΙΣ ΓΙΑ ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 250mg/5ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
paradroxil 250mg/cap caps
bristol myers squibb aebe - amoxicillin trihydrate - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 250mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
paradroxil 500mg/5ml pd.ora.sus
bristol myers squibb aebe - amoxicillin - ΚΟΝΙΣ ΓΙΑ ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 500mg/5ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
paradroxil 500mg/cap caps
bristol myers squibb aebe - amoxicillin - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 500mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
paradroxil 1g/tab tab
bristol myers squibb aebe - amoxicillin - ΔΙΣΚΙΟ - 1g/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
paraplatin 50mg/vial ly.pd.inj
bristol myers squibb aebe - carboplatin - ΕΝΕΣΙΜΟ ΛΥΟΦΙΛΟ - 50mg/vial - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
paraplatin 150mg/vial ly.pd.inj
bristol myers squibb aebe - carboplatin - ΕΝΕΣΙΜΟ ΛΥΟΦΙΛΟ - 150mg/vial - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ